ophthalmic solutions

Summary

Summary: Sterile solutions, essentially free from foreign particles and suitably compounded and dispensed, for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. (From Dorland, 27th ed)

Top Publications

  1. ncbi Preservatives in eyedrops: the good, the bad and the ugly
    Christophe Baudouin
    Department of Ophthalmology III, Quinze Vingts National Ophthalmology Hospital, INSERM, U968, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, CNRS, UMR_7210, Paris F 75012, France
    Prog Retin Eye Res 29:312-34. 2010
  2. ncbi The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
    Michael A Kass
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Ophthalmol 120:701-13; discussion 829-30. 2002
  3. ncbi Management of dry eye disease
    Michael A Lemp
    Georgetown University, and OcuSense, Inc, Washington, DC, USA
    Am J Manag Care 14:S88-101. 2008
  4. ncbi Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial
    M Cristina Leske
    Department of Preventive Medicine, Stony Brook University School of Medicine, Health Sciences Center, L3 086, Stony Brook, NY 11794 8036, USA
    Arch Ophthalmol 121:48-56. 2003
  5. ncbi Combined application of autologous serum eye drops and silicone hydrogel lenses for the treatment of persistent epithelial defects
    Jin A Choi
    Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, St Vincent s Hospital, Suwon, Korea
    Eye Contact Lens 37:370-3. 2011
  6. ncbi Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis
    Karly P Garnock-Jones
    Adis, Auckland, New Zealand
    Drugs 72:361-73. 2012
  7. ncbi A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome
    Leopoldo Baiza-Duran
    Laboratorios Sophia, S A de C V, Av Paseo del Norte 5255, Guadalajara Technology Park, Zapopan, Jalisco, Mexico
    Br J Ophthalmol 94:1312-5. 2010
  8. ncbi Eye mucosa: an efficient vaccine delivery route for inducing protective immunity
    Kyoung Yul Seo
    Institute for Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
    J Immunol 185:3610-9. 2010
  9. ncbi The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa
    Yasuhiro Ikeda
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Higashi ku, Fukuoka 812 8582, Japan
    Graefes Arch Clin Exp Ophthalmol 250:809-14. 2012
  10. ncbi Clinical performance of a mid-viscosity artificial tear for dry eye treatment
    Peter A Simmons
    Eye Care Research and Development, Allergan LLC, Irvine, CA 92612, USA
    Cornea 26:294-302. 2007

Detail Information

Publications338 found, 100 shown here

  1. ncbi Preservatives in eyedrops: the good, the bad and the ugly
    Christophe Baudouin
    Department of Ophthalmology III, Quinze Vingts National Ophthalmology Hospital, INSERM, U968, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, CNRS, UMR_7210, Paris F 75012, France
    Prog Retin Eye Res 29:312-34. 2010
    ..roles of the active compound and the preservative in inducing the toxic and/or proinflammatory effects of ophthalmic solutions, is still being debated...
  2. ncbi The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
    Michael A Kass
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Ophthalmol 120:701-13; discussion 829-30. 2002
    ..There is no consensus on the efficacy of medical treatment in delaying or preventing the onset of POAG in individuals with elevated IOP. Therefore, we designed a randomized clinical trial, the Ocular Hypertension Treatment Study...
  3. ncbi Management of dry eye disease
    Michael A Lemp
    Georgetown University, and OcuSense, Inc, Washington, DC, USA
    Am J Manag Care 14:S88-101. 2008
    ..Treatment selection is guided primarily by DED severity. Recently published guidelines propose a severity classification based on clinical signs and symptoms, with treatment recommendations according to severity level...
  4. ncbi Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial
    M Cristina Leske
    Department of Preventive Medicine, Stony Brook University School of Medicine, Health Sciences Center, L3 086, Stony Brook, NY 11794 8036, USA
    Arch Ophthalmol 121:48-56. 2003
    ..To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT), including the effect of EMGT treatment...
  5. ncbi Combined application of autologous serum eye drops and silicone hydrogel lenses for the treatment of persistent epithelial defects
    Jin A Choi
    Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, St Vincent s Hospital, Suwon, Korea
    Eye Contact Lens 37:370-3. 2011
    ..We investigated the utility of a combination of autologous serum eye drops and a silicone-hydrogel (SH) lens in the treatment of persistent epithelial defects (PEDs)...
  6. ncbi Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis
    Karly P Garnock-Jones
    Adis, Auckland, New Zealand
    Drugs 72:361-73. 2012
    ..Azithromycin 1.5% ophthalmic solution was well tolerated in patients with bacterial or trachomatous conjunctivitis. Most events were of mild to moderate severity...
  7. ncbi A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome
    Leopoldo Baiza-Duran
    Laboratorios Sophia, S A de C V, Av Paseo del Norte 5255, Guadalajara Technology Park, Zapopan, Jalisco, Mexico
    Br J Ophthalmol 94:1312-5. 2010
    ..To evaluate the efficacy and safety of two different concentrations of cyclosporine A (CsA) in aqueous solution compared to vehicle in patients with dry eye syndrome...
  8. ncbi Eye mucosa: an efficient vaccine delivery route for inducing protective immunity
    Kyoung Yul Seo
    Institute for Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
    J Immunol 185:3610-9. 2010
    ..On the basis of these findings, we propose that the eyedrop route is an alternative to mucosal routes for administering vaccines...
  9. ncbi The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa
    Yasuhiro Ikeda
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Higashi ku, Fukuoka 812 8582, Japan
    Graefes Arch Clin Exp Ophthalmol 250:809-14. 2012
    ..The objective of this work was to evaluate the clinical efficacy of a topical dorzolamide (a carbonic anhydrase inhibitor) in CME associated with RP...
  10. ncbi Clinical performance of a mid-viscosity artificial tear for dry eye treatment
    Peter A Simmons
    Eye Care Research and Development, Allergan LLC, Irvine, CA 92612, USA
    Cornea 26:294-302. 2007
    ..We report the results of 3 studies conducted to evaluate the performance of a 1.0% carboxymethylcellulose (CMC) mid-viscosity artificial tear compared to currently marketed low-viscosity tears...
  11. ncbi Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension
    Almira Chabi
    Merck Sharp and Dohme Corp, PO Box 1000, North Wales, PA 19454 1099, USA
    Am J Ophthalmol 153:1187-96. 2012
    ..To compare the efficacy and safety of tafluprost, a preservative-free (PF) prostaglandin analogue, with PF timolol in patients with open-angle glaucoma or ocular hypertension...
  12. pmc Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay
    Hong Liang
    Paris Descartes University, Faculty of Biological and Pharmacological Sciences, Department of Toxicology, Paris, France
    Mol Vis 15:1690-9. 2009
    ..005% latanoprost, 0.004% travoprost, 0.03% bimatoprost (containing 0.02%, 0.015%, and 0.005% BAC, respectively), and 0.005% latanoprost in a new cationic emulsion (LCEm) formulation...
  13. ncbi Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction
    Henry D Perry
    Ophthalmic Consultants of Long Island, Rockville Centre, New York 11570, USA
    Cornea 25:171-5. 2006
    ..To investigate the efficacy of topical cyclosporine A 0.05% (tCsA) (Restasis, Allergan Pharmaceuticals) in the treatment of meibomian gland dysfunction (posterior blepharitis)...
  14. ncbi Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression
    Canan Gürdal
    Ankara Ataturk Training and Research Hospital, 2nd Ophthalmology Department, Ankara, Turkey
    Curr Eye Res 35:771-7. 2010
    ..To evaluate the effects of topical cyclosporine A (CsA) 0.05% (Restasis) on the signs and symptoms of dry eye, on apoptosis, and on MMP-9 expression in conjunctiva epithelial cells in thyroid orbitopathy (TO)-related dry eye patients...
  15. pmc Topical ocular delivery of NSAIDs
    Munish Ahuja
    Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, 125 001, Haryana, India
    AAPS J 10:229-41. 2008
    ..NSAIDs are weak acids with pKa mostly between 3.5 and 4.5, and are poorly soluble in water. Aqueous ophthalmic solutions of NSAIDs have been made using sodium, potassium, tromethamine and lysine salts or complexing with ..
  16. ncbi Autologous serum eye drops for the treatment of dry eye diseases
    Takashi Kojima
    Department of Ophthalmology, Social Insurance Chukyo Hospital, Nagoya, Japan
    Cornea 27:S25-30. 2008
    ..The biological background of AS eye drops and previous clinical studies of these medications for the treatment of dry eye are discussed...
  17. ncbi The economic burden of dry eye: a conceptual framework and preliminary assessment
    Prabashni Reddy
    Abt Associates Inc, 55 Wheeler Street, Cambridge, Massachusetts 02138, USA
    Cornea 23:751-61. 2004
    ..To develop a conceptual framework for analyzing the economic burden of dry eye and a preliminary assessment of key factors that contribute to that burden...
  18. ncbi A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance
    Stephen C Pflugfelder
    Baylor College of Medicine, Houston, Texas, USA
    Am J Ophthalmol 138:444-57. 2004
    ..To evaluate loteprednol etabonate ophthalmic 0.5% suspension, versus placebo for treatment of the inflammatory component of keratoconjunctivitis sicca in patients with delayed tear clearance...
  19. ncbi [A new approach for better comprehension of diseases of the ocular surface]
    C Baudouin
    Centre National d Ophtalmologie des Quinze Vingts, Paris, France
    J Fr Ophtalmol 30:239-46. 2007
    ....
  20. ncbi Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model
    T Fujihara
    Santen Pharmaceutical Co, Ltd, Nara Research and Development Center, Japan
    Invest Ophthalmol Vis Sci 42:96-100. 2001
    ..Accordingly, the effects of such an agonist INS365 on these parameters were characterized in a rat dry eye model...
  21. ncbi Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells
    David A Ammar
    Rocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver School of Medicine, Aurora, 80045, USA
    Adv Ther 27:837-45. 2010
    ..Substitution of BAK with polyquad or sofZia resulted in significantly higher percentages of live conjunctival and corneal cells. Further studies are needed to understand the- clinical implications of these findings...
  22. ncbi Minimal clinically important difference for the ocular surface disease index
    Kimberly L Miller
    ICON Clinical Research, 188 Embarcadero, Ste 200, San Francisco, CA 94105, USA
    Arch Ophthalmol 128:94-101. 2010
    ....
  23. ncbi Periocular routes for retinal drug delivery
    Swita Raghava
    University of Nebraska Medical Centre, Department of Pharmaceutical Sciences, Omaha, NE 68198 5840, USA
    Expert Opin Drug Deliv 1:99-114. 2004
    ..In the coming years, several innovations in absorption enhancement, drug delivery systems and drug administration devices are anticipated for improving retinal drug delivery via periocular routes...
  24. ncbi Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase
    Yoriko Nakanishi
    Division of Ophthalmology, Department of Organs Therapeutics, Kobe University Graduate School of Medicine, 7 5 2 Kusunoki cho, Chuo Ku, Kobe 650 0017, Japan
    Exp Eye Res 83:1108-17. 2006
    ..05), but not of Akt. Taken together, the present findings suggest that latanoprost rescues retinal neurons and/or glial cells from apoptosis, which is probably mediated by p44/p42 MAPK through caspase-3 inhibition...
  25. ncbi Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A
    F Brignole
    Laboratory of Immunohematology and the. Department of Ophthalmology, , APHP, , Boulogne, France
    Invest Ophthalmol Vis Sci 42:90-5. 2001
    ..This study confirms that cyclosporin A may be efficient in reducing conjunctival inflammation in moderate to severe KCS and is consistent with clinical results in this indication...
  26. pmc Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride
    H Liang
    Department of Toxicology, Faculty of Biological and Pharmacological Sciences, University Paris Descartes, Paris, France
    Br J Ophthalmol 92:1275-82. 2008
    ..To compare the conjunctival and corneal reactions of commercially available solution of latanoprost (Xalatan) and preservative-free (PF) tafluprost in rabbits...
  27. pmc Randomised controlled single-blind study of conventional versus depot mydriatic drug delivery prior to cataract surgery
    Vincent Dubois
    Eye Unit, Royal United Hospital, Combe Park, Bath, B and NES, BA1 3NG, UK
    BMC Ophthalmol 6:36. 2006
    ....
  28. ncbi Evaluation of the effects on conjunctival tissues of Optive eyedrops over one month usage
    M Guillon
    OTG Research and Consultancy, London, UK
    Cont Lens Anterior Eye 33:93-9. 2010
    ..028-0.002). The results demonstrated that the regular use of Optive over one month was significantly superior to Hylocomod in improving conjunctival status by producing a greater reduction in the staining of dry eye sufferers...
  29. pmc 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children
    Isabelle Cochereau
    Service d Ophtalmologie, CHU d Angers, 4, rue Larrey, 49033 Angers, France
    Br J Ophthalmol 91:465-9. 2007
    ..To compare the efficacy and safety of Azyter, azithromycin 1.5% eye drops, for 3 days with tobramycin 0.3% for 7 days to treat purulent bacterial conjunctivitis...
  30. ncbi Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials
    Timothy L Comstock
    Medical Affairs, Global Pharmaceutical, Bausch and Lomb, Inc, Rochester, New York 14609, USA
    Paediatr Drugs 12:105-12. 2010
    ..Besifloxacin is a new topical fluoroquinolone, the first chlorofluoroquinolone, for the treatment of bacterial conjunctivitis...
  31. ncbi Long-term follow up of autologous serum treatment for recurrent corneal erosions
    Nikolaos G Ziakas
    1st Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Clin Experiment Ophthalmol 38:683-7. 2010
    ..The aim of the study was to evaluate long-term results of autologous serum treatment for recurrent corneal erosions...
  32. ncbi Pain management during retinopathy of prematurity eye examinations: a systematic review
    Haifa A Samra
    College of Nursing, South Dakota State University, Brookings, SD 57007, USA
    Adv Neonatal Care 9:99-110. 2009
    ..This is an area where much work is still needed to address the needs of the infant during this critical examination...
  33. ncbi Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye
    Santosh Khanal
    Department of Vision Sciences, Glasgow Caledonian University, Glasgow, United Kingdom
    Cornea 26:175-81. 2007
    ..To determine the effect of an oil-in-water emulsion eye drop compared with a conventional dry eye supplement (hypromellose) on tear physiology in dry eye...
  34. ncbi The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms
    Donald R Korb
    Korb Associates, Boston, MA 02116, USA
    Optom Vis Sci 82:594-601. 2005
    ....
  35. ncbi Efficacy of sucrose to reduce pain in premature infants during eye examinations for retinopathy of prematurity
    Peter Gal
    Pharmacy Division, Greensboro Area Health Education Center, Greensboro, NC 27401 1020, USA
    Ann Pharmacother 39:1029-33. 2005
    ..Sweet solutions have been shown to reduce procedural pain in newborns...
  36. ncbi Evaluation of topical cyclosporine for the treatment of dry eye disease
    Henry D Perry
    Ophthalmic Consultants of Long Island, Ryan Medical Arts Bldg, Ste 402, 2000 N Village Ave, Rockville Centre, New York, NY 11570, USA
    Arch Ophthalmol 126:1046-50. 2008
    ..To evaluate the use of topical cyclosporine, 0.05% (Restasis; Allergan Inc, Irvine, California), for the treatment of mild, moderate, and severe dry eye disease unresponsive to artificial tears therapy...
  37. ncbi Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome
    Cristhian A Urzua
    Department of Ophthalmology, University of Chile Clinic Hospital, Santiago, Chile
    Curr Eye Res 37:684-8. 2012
    ..To determine symptoms improvement in dry eye patients with short-term autologous serum (AS) eyedrops treatment using the standardized Ocular Surface Disease Index (OSDI) survey...
  38. ncbi Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma
    Jean Francois Rouland
    Service Ophtalmologie, CHRU de Lille, Place de Verdun, Lille 59000, France
    Br J Ophthalmol 97:196-200. 2013
    ....
  39. ncbi Nanomaterials for ocular drug delivery
    Shengyan Liu
    Department of Chemical Engineering, Waterloo Institute for Nanotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L3G1, Canada
    Macromol Biosci 12:608-20. 2012
    ....
  40. ncbi Pupil dilation using a pledget sponge: a randomized controlled trial
    Austin McCormick
    Department of Ophthalmology, Arrowe Park Hospital, Wirral, Merseyside, UK
    Clin Experiment Ophthalmol 34:545-9. 2006
    ..To show that a pledget soaked in mydriatics and placed in the lower conjunctival fornix is as effective as drops in providing mydriasis for cataract surgery...
  41. ncbi The use of autologous serum tears in persistent corneal epithelial defects
    A L Young
    Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, People s Republic of China
    Eye (Lond) 18:609-14. 2004
    ..Autologous serum tears had been demonstrated to be beneficial in the treatment of PED. The current study was conducted to review the local spectrum of indications and to examine the outcome of autologous serum tear usage...
  42. ncbi Topical ophthalmic cyclosporine: pharmacology and clinical uses
    Eric Donnenfeld
    Ophthalmic Consultants of Long Island and Connecticut, Rockville Centre, New York 11570, USA
    Surv Ophthalmol 54:321-38. 2009
    ..As these disorders are often refractory to other available treatments, ophthalmic cyclosporine is a welcome nontoxic adjunct or replacement to potentially toxic topical or systemic immunosuppressive therapies...
  43. pmc Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease
    Kyung Sun Na
    Department of Health Promotion Center, College of Medicine, The Catholic University of Korea, Seoul, St Mary s Hospital, Seoul, Korea
    J Ocul Pharmacol Ther 28:479-83. 2012
    ..To evaluate the therapeutic effect of allogeneic serum eye drops for the treatment of dry eye in patients with chronic graft-versus-host disease (cGVHD) following bone marrow transplantation...
  44. ncbi Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial
    Rajesh Sinha
    Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, 110029, India
    Graefes Arch Clin Exp Ophthalmol 248:1167-72. 2010
    ..To evaluate the efficacy and safety of topical cyclosporine A 2% in the prevention of graft rejection in high-risk keratoplasty...
  45. ncbi German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye
    Carl Erb
    Ophthalmology Department, Schlosspark Clinic, Heubnerweg 2, 14059, Berlin, Germany
    Graefes Arch Clin Exp Ophthalmol 246:1593-601. 2008
    ..The purpose of this register was to determine the links between glaucoma, age, concomitant disease, medication, and dry eye in a large group of glaucoma patients...
  46. ncbi Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects
    Hideki Mochizuki
    Department of Ophthalmology and Visual Science, Graduate School of Biomedical Science, Hiroshima University, Minami Ku, Hiroshima, Japan
    Jpn J Ophthalmol 54:286-90. 2010
    ..To compare the intraocular pressure (IOP) reduction over 24 h achieved with tafluprost (0.0015%) with that achieved with latanoprost (0.005%)...
  47. ncbi ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy
    Kensaku Miyake
    Shohzankai Medical Foundation, Miyake Eye Hospital, Nagoya, Japan
    J Cataract Refract Surg 29:1800-10. 2003
    ....
  48. ncbi A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome
    Eun Chul Kim
    Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea
    Am J Ophthalmol 147:206-213.e3. 2009
    ..To compare the efficacy of vitamin A (retinyl palmitate) and cyclosporine A 0.05% eye drops in treating patients with dry eye disease...
  49. ncbi Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis
    Adil Kilic
    Department of Opthalmology, Tatvan Military Hospital, Turkey
    Can J Ophthalmol 41:693-8. 2006
    ..A double-masked, placebo-controlled trial to evaluate the short-term efficacy and safety of topical 2% cyclosporine A in preservative-free artificial tears for patients with vernal keratoconjunctivitis...
  50. ncbi Clinical review: topical ophthalmic use of cyclosporin A
    Canan Asli Utine
    The Ocular Surface Diseases and Dry Eye Clinic, The Wilmer Eye Institute, Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, MD 21287, USA
    Ocul Immunol Inflamm 18:352-61. 2010
    ..This article aims to evaluate the peer-reviewed published scientific literature and to define well-established uses of CsA eyedrops in the field of ocular surface diseases...
  51. pmc Acupuncture for dry eye: a multicentre randomised controlled trial with active comparison intervention (artificial tear drop) using a mixed method approach protocol
    Tae Hun Kim
    Acupuncture, Moxibustion and Meridian Research Centre, Korea Institute of Oriental Medicine, Daejeon, South Korea
    Trials 11:107. 2010
    ..Therefore, this study was designed both to avoid the flaws of the existing trials and to assess the effectiveness, cost-effectiveness and qualitative characteristics of acupuncture treatment for dry eye...
  52. ncbi Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis
    Bennie H Jeng
    Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA
    Cornea 30:958-61. 2011
    ....
  53. ncbi The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study
    Jost Hillenkamp
    The Eye Hospital, Heinrich Heine University, Dusseldorf, Germany
    Ophthalmology 109:845-50. 2002
    ..To evaluate the efficacy of cidofovir 1% eyedrops with and without cyclosporin A 1% eyedrops as a treatment of acute adenoviral keratoconjunctivitis (AKC)...
  54. ncbi Lactoferrin protects against UV-B irradiation-induced corneal epithelial damage in rats
    T Fujihara
    Santen Pharmaceutical Co, Ltd Nara Research and Development Center, Ikoma shi, Japan
    Cornea 19:207-11. 2000
    ..To investigate the protective effect of lactoferrin containing eyedrops against UV-B-induced corneal damage in vivo, we examined lactoferrin efficacy in a rat UV-B keratitis model...
  55. ncbi Ocular preservatives: associated risks and newer options
    Indu Pal Kaur
    University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
    Cutan Ocul Toxicol 28:93-103. 2009
    ..Reasons for discontinuing traditional preservatives and the need for less-toxic molecules are discussed at length, along with newer options coming up in this area...
  56. ncbi Occludin gene expression as an early in vitro sign for mild eye irritation assessment
    Marisa Meloni
    VitroScreen, In Vitro Research Laboratories, Milano, Italy
    Toxicol In Vitro 24:276-85. 2010
    ....
  57. pmc Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model
    Su Khoh-Reiter
    Drug Safety Research and Development, Pfizer Inc, San Diego, CA 92121, USA
    BMC Ophthalmol 9:5. 2009
    Benzalkonium chloride (BAC) is a common preservative used in ophthalmic solutions. The aim of this study was to compare the cytotoxic effects of BAC-containing ophthalmic solutions with a BAC-free ophthalmic solution using an organotypic ..
  58. pmc Trehalose protects corneal epithelial cells from death by drying
    T Matsuo
    Department of Ophthalmology, Okayama University Medical School, Okayama City 700 8558, Japan
    Br J Ophthalmol 85:610-2. 2001
    ..This study was designed to examine whether trehalose could protect corneal epithelial cells in culture from death by desiccation in order to test trehalose as a potential new eye drop for dry eye syndrome...
  59. ncbi Dry eye in diabetic patients
    Igor Kaiserman
    Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel
    Am J Ophthalmol 139:498-503. 2005
    ..To compare the prevalence of keratoconjunctivitis sicca (KCS) in a prospective cohort of 22,382 diabetic patients with that in the general population...
  60. ncbi Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects
    Bennie H Jeng
    Cole Eye Institute, Cleveland Clinic, OH, USA
    Cornea 28:1104-8. 2009
    ..To evaluate the success rate of treating persistent corneal epithelial defects using 50% autologous serum eyedrops...
  61. ncbi The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study
    Takashi Kojima
    Department of Ophthalmology, Social Insurance Chukyo Hospital, Aichi, Japan
    Am J Ophthalmol 139:242-6. 2005
    ..To evaluate the effectiveness of the autologous serum eyedrops in the treatment of severe dry eye patients...
  62. ncbi Trehalose protects against ocular surface disorders in experimental murine dry eye through suppression of apoptosis
    Wei Chen
    School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical College, 270 Xue Yuan West Road, Wenzhou, Zhejiang 325027, China
    Exp Eye Res 89:311-8. 2009
    ..Trehalose produces some of the same responses as serum upon topical application and can maintain corneal health...
  63. pmc A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients
    Antonio Martinez
    Glaucoma, Instituto Gallego de Oftalmologia, Santiago de Compostela, La Coruna, Spain
    J Ocul Pharmacol Ther 25:239-48. 2009
    ..To compare the effect on the retrobulbar hemodynamics and intraocular pressure (IOP) of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5% in patients with primary open-angle glaucoma (POAG)...
  64. ncbi Locally administered ocular corticosteroids: benefits and risks
    Charles N J McGhee
    Discipline of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Drug Saf 25:33-55. 2002
    ..This extensive review assesses the therapeutic benefits of locally administered ocular corticosteroids in the context of the risks of adverse effects...
  65. ncbi Ocular symptoms and signs with preserved and preservative-free glaucoma medications
    N Jaenen
    UZ Sint Rafael, Leuven, Belgium
    Eur J Ophthalmol 17:341-9. 2007
    ..To compare the prevalence of side effects between eyedrops with or without preservatives, in terms of subjective symptoms and objective signs in patients with open-angle glaucoma...
  66. ncbi An objective evaluation of eyedrop instillation in patients with glaucoma
    Jennifer L Stone
    Wilmer Eye Institute, The Johns Hopkins University, 6115 Falls Rd, Third Floor, Baltimore, MD 21209 2226, USA
    Arch Ophthalmol 127:732-6. 2009
    ..To evaluate the performance of patients with ocular hypertension and glaucoma who are experienced in the instillation of topical ocular hypotensive medications...
  67. ncbi Are multidose over-the-counter artificial tears adequately preserved?
    Colin Charnock
    Department of Health Sciences, Oslo University College, Oslo, Norway
    Cornea 25:432-7. 2006
    ..Based on the challenge test outlined in the European Pharmacopoeia, products were tested in their original containers to see whether their component preservative had sufficient activity...
  68. pmc Autologous serum eye drops for ocular surface disorders
    G Geerling
    Department of Ophthalmology, University of Lubeck, Ratzeburger Allee 160, D 23538, Germany
    Br J Ophthalmol 88:1467-74. 2004
    ..In view of legislative restrictions and based upon the literature reviewed here a preliminary standard operating procedure for the manufacture of serum eye drops is proposed...
  69. ncbi Chitosan based nanocarriers for indomethacin ocular delivery
    Alia A Badawi
    Department of Pharmaceutics and Industrial Pharmacy, Pharmacy College, Cairo University, Cairo, Egypt
    Arch Pharm Res 31:1040-9. 2008
    ..Therefore, CS nanocarriers developed in this study were able to contact intimately with the cornea providing slow gradual IM release with long-term drug level thereby increasing delivery to both external and internal ocular tissues...
  70. ncbi Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children
    Michael X Repka
    Jaeb Center for Health Research, Tampa, FL 33647, USA
    Arch Ophthalmol 123:149-57. 2005
    ..To compare patching and atropine sulfate as treatments for moderate amblyopia in children 18 months after completion of a 6-month randomized trial...
  71. ncbi Autologous serum eye drops for dry eye after LASIK
    Tomoko Noda-Tsuruya
    Minamiaoyama Eye Clinic, Tokyo, Japan
    J Refract Surg 22:61-6. 2006
    ..To evaluate the efficacy of autologous serum eye drops for dry eye after LASIK in a prospective, randomized study...
  72. pmc Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease
    B A Noble
    Department of Ophthalmology, Clarendon Wing, The General Infirmary at Leeds, Belmont Grove, Leeds LS2 9NS, UK
    Br J Ophthalmol 88:647-52. 2004
    ..To evaluate the efficacy of 50% autologous serum drops against conventional treatment in ocular surface disorders refractory to normal treatments in a prospective randomised crossover trial...
  73. ncbi Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis
    Sibel Bozdag
    Department of Pharmaceutical Technology, Hacettepe University, Sihhiye, Ankara, Turkey
    Eur J Pharm Biopharm 70:260-9. 2008
    ..2% and 85.3% of CH were released from the viscous solutions containing 1.5% and 1% HPMC, respectively, in 8h. No irritation was observed when the viscous solutions were tested on rabbit and human eyes...
  74. ncbi Nanotechnology in ocular drug delivery
    Sanjeeb K Sahoo
    Laboratory of Nanomedicine, Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar 751 023, India
    Drug Discov Today 13:144-51. 2008
    ....
  75. ncbi Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells
    Masahiko Ayaki
    Department of Ophthalmology, Fujigaoka Hospital, Showa University School of Medicine, Aobaku Yokohama, Kanagawa, Japan
    Clin Experiment Ophthalmol 36:553-9. 2008
    The cytotoxicity of a range of commercial ophthalmic solutions in the presence and absence of preservatives was assessed in human corneal endothelial cells (HCECs), corneal epithelia and conjunctival epithelia using in vitro techniques.
  76. pmc Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations
    Gary N Foulks
    Department of Ophthalmology and Vision Science, University of Louisville, 301 E Muhammad Ali Blvd, Louisville, KY 40202, USA
    Cornea 29:781-8. 2010
    ....
  77. ncbi Acute corneal epithelial change after instillation of benzalkonium chloride evaluated using a newly developed in vivo corneal transepithelial electric resistance measurement method
    Masafumi Uematsu
    Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
    Ophthalmic Res 39:308-14. 2007
    ..Acute corneal permeability change after instillation of benzalkonium chloride (BAC) was evaluated using a newly developed in vivo corneal transepithelial electric resistance (TER) measurement method...
  78. ncbi Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen cha
    Mark B Abelson
    Ora, Inc, Andover, Massachusetts 01810, USA
    Clin Ther 31:1908-21. 2009
    ..Based on a history of clinical effectiveness and tolerability of oral bepotastine besilate in the treatment of allergic symptoms, bepotastine besilate is being tested as a potential ophthalmic medication for allergic conjunctivitis...
  79. pmc Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone
    J Shimazaki
    Department of Ophthalmology, Tokyo Dental College, Chiba, Japan
    Br J Ophthalmol 84:1250-4. 2000
    ..A beta blocker (0.5% timolol) and a novel prostaglandin F(2alpha) metabolite related drug (0.12% unoprostone) were examined in a prospective, randomised fashion...
  80. ncbi Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production
    Stephen C Pflugfelder
    Ocular Surface Center, Baylor College of Medicine, Houston, TX, USA
    Cornea 27:64-9. 2008
    ..To evaluate the effects of sequential treatment with artificial tears and cyclosporine emulsion on conjunctival goblet cell density and production of transforming growth factor (TGF)-beta2 in patients with dry eye disease...
  81. ncbi The pathology of dry eye: the interaction between the ocular surface and lacrimal glands
    M E Stern
    Department of Biological Sciences, Allergan, Inc, Irvine, CA 92713 9534, USA
    Cornea 17:584-9. 1998
    ....
  82. ncbi Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies
    Gang Wei
    School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
    J Control Release 83:65-74. 2002
    ..However, no further improvement in the ocular retention was observed when adding HA-Na into the thermosetting gel due to the substantially decreased gel strength...
  83. ncbi Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects
    William C Stewart
    Pharmaceutical Research Network, Charleston, SC 29412 2464, USA
    J Glaucoma 12:475-9. 2003
    ..To evaluate short-term conjunctival and corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy individuals...
  84. ncbi Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension
    J Thygesen
    Department of Ophthalmology, Vejle Sygehus, Denmark
    Acta Ophthalmol Scand 78:37-44. 2000
    ..To investigate and compare the short term effects of topical latanoprost and timolol on the tear fluid and ocular surface condition in patients with bilateral primary open angle glaucoma or ocular hypertension...
  85. pmc Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study
    K Kamiya
    Department of Ophthalmology, University of Kitasato School of Medicine, Kanagawa 252 0374, Japan
    Eye (Lond) 26:1363-8. 2012
    ..To assess the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome...
  86. ncbi In vitro comparison of the cytotoxic effects of clinically available ophthalmic solutions of fluoroquinolones on human keratocytes
    Rita Mencucci
    Department of Oto Neuro Ophthalmological Surgical Sciences, University of Florence, Florence, Italy
    Can J Ophthalmol 46:513-20. 2011
    ..To compare the cytotoxic effects of preserved versus unpreserved commercially available ophthalmic preparations of fluoroquinolones on human keratocytes in vitro...
  87. ncbi Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis
    Michael Rubin
    Department of Ophthalmology, University of Chicago, Chicago, IL 60605, USA
    J Ocul Pharmacol Ther 22:47-53. 2006
    ..These findings should be further evaluated in large-scale, controlled, clinical trials...
  88. ncbi The diagnosis and management of dry eye: a twenty-five-year review
    S C Pflugfelder
    Ocular Surface and Tear Center, Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Florida, USA
    Cornea 19:644-9. 2000
    ..To review the advances in the diagnosis, pathogenesis, and management of dry eye disease in the past 25 years...
  89. ncbi Diquafosol ophthalmic solution for dry eye treatment
    Masatsugu Nakamura
    Research and Development Division, Santen Pharmaceutical Co, Ltd, 8916 16, Takayama cho, Ikoma shi, Nara 630 0101, Japan
    Adv Ther 29:579-89. 2012
    ..Various types of dry eye treatment drugs have been developed. This review summarizes the basic and clinical research carried out in the development of diquafosol for ophthalmic use...
  90. ncbi Time- and temperature-dependent stability of growth factor peptides in human autologous serum eye drops
    Jay C Bradley
    Department of Ophthalmology and Visual Sciences, University of California at Davis, Sacramento, CA, USA
    Cornea 28:200-5. 2009
    ..To determine optimum storage conditions for AS eye drops by measuring the concentration of growth factor peptides (GFP) as a function of storage temperature and storage duration...
  91. ncbi Comparison of mydriatic efficacy of spray application and drop instillation of tropicamide 1%
    A Akman
    Baskent University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey
    Eye (Lond) 13:653-5. 1999
    ..To determine whether the mydriatic efficacy of spray application of tropicamide 1% is comparable to drop instillation of tropicamide 1%, and to compare the ocular discomfort caused by these methods...
  92. ncbi Toxic keratopathy associated with abuse of low-dose anesthetic: a case report
    Hsiao Ting Chen
    Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
    Cornea 23:527-9. 2004
    ..To describe the clinical course and treatment of toxic keratopathy associated with abuse of topical anesthetic at a very low concentration, 0.05%...
  93. ncbi Effects of autologous serum eye drops on corneal wound healing after superficial keratectomy in rabbits
    Ilknur Akyol-Salman
    Department of Ophthalmology, Ataturk University Faculty of Medicine, Erzurum, Turkey
    Cornea 25:1178-81. 2006
    ..To study the effects of topically applied autologous serum on the wound healing process of mechanically produced corneal ulcers...
  94. ncbi Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin
    Chandrasekar Durairaj
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, Colorado 80045, USA
    Invest Ophthalmol Vis Sci 51:5804-16. 2010
    ..The purpose of this study was to develop a DPT that could serve as an ophthalmic delivery vehicle for gatifloxacin and to evaluate its in vitro and in vivo delivery after topical application...
  95. ncbi Topical anesthetic abuse keratopathy: a commonly overlooked health care problem
    Ayse Yagci
    Department of Ophthalmology, Faculty of Medicine, Ege University, Izmir, Turkey
    Cornea 30:571-5. 2011
    ..To evaluate the clinical course, treatment modality, factors affecting the epithelization period, and visual outcome in patients with topical anesthetic abuse keratopathy...
  96. ncbi Effectiveness of 100% autologous serum drops in ocular surface disorders
    A Jover Botella
    Servicio de Farmacia, Hospital General Universitario de Alicante, Alicante, Espana
    Farm Hosp 35:8-13. 2011
    ..To evaluate the effectiveness of 100% autologous serum eye drops for the treatment of various ocular surface disorders...
  97. pmc Compliance and adherence in glaucoma management
    Alan Robin
    Department of Glaucoma, University of Maryland, and Johns Hopkins University, 6115 Falls Road, Suite 333, Baltimore, MD, USA
    Indian J Ophthalmol 59:S93-6. 2011
    ..Maximizing patient adherence to medication has the potential to reduce the number of surgical interventions required to treat glaucoma, prevent unnecessary vision loss, and save the overall healthcare system money in the long run...
  98. ncbi Comparative randomised controlled clinical trial of a herbal eye drop with artificial tear and placebo in computer vision syndrome
    N R Biswas
    Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029
    J Indian Med Assoc 101:208-9, 212. 2003
    ..01). No side-effects were noted by any of the drugs. Both subjective and objective improvements were observed in itone treated cases. So, itone can be considered as a useful drug in computer vision syndrome...
  99. ncbi Comparison of human ocular distribution of bimatoprost and latanoprost
    Parul Ichhpujani
    Anne V Goldberg Glaucoma Service, Willis Eye Institute, Philadelphia, PA, USA
    J Ocul Pharmacol Ther 28:134-45. 2012
    ..03% bimatoprost or 0.005% latanoprost for understanding concentration-activity relationships...
  100. ncbi The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo
    Pertti Pellinen
    Santen Oy, Tampere, Finland
    Curr Eye Res 37:145-54. 2012
    To investigate the cytotoxicity of benzalkonium chloride (BAC)-containing ophthalmic solutions of prostaglandin analogs (latanoprost, travoprost, bimatoprost, and preservative-free (PF) tafluprost), BAC mixture (BACmix) and BAC homologs ..

Research Grants64

  1. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2013
    ..Also, there will be a measurement of pressure in the eye and thickness of the cornea. To study patients'DNA, the researchers will obtain a bloo..
  2. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
    ..Also, there will be a measurement of pressure in the eye and thickness of the cornea. To study patients'DNA, the researchers will obtain a bloo..
  3. Therapeutic Effect of a Novel Antioxidant on Degenerative Eye Disorders
    Nuran Ercal; Fiscal Year: 2012
    ..NACA eye drops would represent an alternative to costly cataract surgery, reduce health care costs related to age-related eye diseases and greatly improve the quality of life of people affected by these diseases. ..
  4. Pharmacology of Intravesical Antisense Based Therapy for Over Active Bladder
    Naoki Yoshimura; Fiscal Year: 2013
    ..The long-term objectives of the research program are to establish new and effective therapeutic targets and/or interventions strategies for the treatment of OAB. ..
  5. Aspheric SDOCT Imaging System for Dry Eye and Cornea Diagnostics
    ERIC L BUCKLAND; Fiscal Year: 2012
    ....
  6. Characterization of purified myocilin: glaucoma as a protein misfolding disease
    Raquel L Lieberman; Fiscal Year: 2013
    ....
  7. PROOF OF CONCEPT FOR ANTIMICROBIAL PROPERTIES OF LACRITIN IN VIVO
    John D Sheppard; Fiscal Year: 2010
    ....
  8. Topical Nanoparticles for CNV
    Uday B Kompella; Fiscal Year: 2010
    ..Such an approach avoids the pitfalls associated with invasive drug administrations. The proposed technologies are likely to benefit various drugs intended for treating diseases of the back of the eye. ..
  9. Long-Acting Mucus-Penetrating Steroid Particles for Treatment of Eye Inflammation
    Hongming Chen; Fiscal Year: 2011
    ....
  10. Molecular and Clinical Pharmacology of Retinopathy of Prematurity
    Jacob V Aranda; Fiscal Year: 2013
    ..The NYPD-PRC will surely elevate the level of scientific inquiry on molecular and clinical pharmacology of ROP to hasten its prevention and avert life-long blindness. ..
  11. Advanced Imaging for Glaucoma
    David Huang; Fiscal Year: 2012
    ..Accurate monitoring of glaucoma with OCT will improve treatment decisions regarding surgery or eye drops, both of which are effective but also carry significant side effects and risks. ..
  12. Topical delivery of nanoencapsulated plasmid DNA to posterior ocular targets
    Gretchen M Unger; Fiscal Year: 2012
    ..The aim of this project is to develop a safe and effective way to deliver these treatments. ..
  13. Transscleral Drug Delivery for Retinal Disorders
    HENRY FRANCIS EDELHAUSER; Fiscal Year: 2010
    ..These delivery techniques should be safer and more effective than the state of the art. Ultimately, these results will guide us in enhancing drug treatments in ophthalmic practice. ..
  14. Ocular Drug Delivery Devices for Improved Postoperative Cataract Care
    Buddy D Ratner; Fiscal Year: 2010
    ....
  15. Modifiable Risk Factors for CME in Retinitis Pigmentosa
    Michael A Sandberg; Fiscal Year: 2010
    ....
  16. Ocular Insert for Non-Invasive Sustained Drug Delivery for the Treatment of Glauc
    CHARLES DANIEL contact LEAHY; Fiscal Year: 2010
    ..It will also reduce the current 24-59% level of non-compliance by remaining in the eye between physician visits (1). ..
  17. Drug Eluting Contact Lenses
    Joseph B Ciolino; Fiscal Year: 2013
    ..More importantly, they would offer the possibility of treating eye diseases with a host of medications that cannot currently be delivered in a drop form. ..
  18. Novel emulsion-based formulation of the anti-glaucoma MSH-1001 for improved topic
    Ronald A Wassel; Fiscal Year: 2011
    ..The goal of this proposal is to develop a clinical ophthalmic emulsion of MSH-1001, a novel small molecule that effectively lowers IOP by enhancing the trabecular outflow through a novel mechanism of action,. . ..
  19. Gene Delivery in Retinal Diseases
    John M Nickerson; Fiscal Year: 2013
    ..Impact on Field: This research should improve gene delivery to the point that a patient can self- treat with eye drops. The use of topical eye drops to deliver gene therapy agents to the posterior segment and the RPE is transformative. ..
  20. Dual Leucine Zipper Kinase (DLK) as a Mediator of Retinal Ganglion Cell Injury
    Donald J Zack; Fiscal Year: 2013
    ..abstract_text> ..
  21. Structural models to untangle triggers of ocular/nonocular herpesvirus recurrence
    Stephen R Cole; Fiscal Year: 2012
    ..g., sunglasses designed to block critical UV wavelengths or UV blocking eye drops) to reduce morbidity. (e.g., sunglasses designed to block critical UV wavelengths or UV blocking eye drops) ..
  22. A Phase II Study of OT-551 Antioxidant Eye Drop
    Darby Thompson; Fiscal Year: 2009
    ..Participants will have one eye randomized to receive the eye drop and the fellow eye will be observed only. ..
  23. In Vitro-In Vivo Correlation of Ocular Implants
    Uday B Kompella; Fiscal Year: 2013
    ..For generic ophthalmic solutions that are qualitatively (Q1) and quantitatively (Q2) the same as the RLD, bioequivalence is considered to be ..
  24. Comparative Effectiveness of Prophylaxis in Cataract Surgery
    Lisa J Herrinton; Fiscal Year: 2013
    ....
  25. An RNAi Screen for Genes that Modulate Retinal Ganglion Cell Survival
    Donald J Zack; Fiscal Year: 2013
    ....
  26. Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavai
    Uday B Kompella; Fiscal Year: 2012
    ..For generic ophthalmic solutions that are qualitatively (Q1) and quantitatively (Q2) the same as the RLD, bioequivalence is considered to be ..
  27. A Novel Adherence Technology for Ophthalmic Medications
    VESTA BRUE; Fiscal Year: 2013
    ..It includes a drop dispensing device that assures only one drop is properly applied to the eye in sterile, safe, and correct application with infrared monitoring. ..
  28. A Novel Treatment for Keratoconus and Keratectasias using Nitro Technology
    David C Paik; Fiscal Year: 2010
    ..The latter conditions are devastating, long-term (5-10 years) complications following LASIK procedures. They were previously unpredicted and are currently of unknown epidemiologic proportion. ..
  29. OCULAR INSERT FOR THE TREATMENT OF GLAUCOMA
    CHARLES LEAHY; Fiscal Year: 2001
    ..Define a prototype design for a polymeric insert of the human inferior conjunctival sac. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE ..
  30. Drug Discovery for Diabetic Retinopathy
    ZOYA DEMIDENKO; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  31. Ultra-Sonic Non-Contact Tonometer in Glaucoma-IOP Checks
    Peter Gross; Fiscal Year: 2005
    ..Phase I of the project will end with a working model of the USNCT that demonstrates the feasibility of the method in a model eye with IOP controlled by intracameral manometry. ..
  32. Bioartificial Lacrimal Gland
    Samuel Yiu; Fiscal Year: 2005
    ....
  33. DEVICE TO AID SELF ADMINISTRATION OF EYEDROPS
    GEORGE FRIED; Fiscal Year: 2001
    ..It will be a simple, low cost device with large health and cost benefits to the public. ..
  34. TIME RELEASE OPHTHALMIC DRUG DELIVERY INSERT
    BRUCE COHAN; Fiscal Year: 2000
    ..In The United States alone glaucoma affects at least 3 million people and involves a pharmaceutical market of $785 million. ..
  35. A Real Time Monitoring System to Measure IOP in Glaucoma
    DOUG JACKSON; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  36. ANTIMICROBIAL PEPTIDES TO TREAT BACTERIAL KERATITIS
    KATHRYN CRAWFORD; Fiscal Year: 2004
    ..determine the chemical and toxicological suitability of these molecules for use as potential antimicrobial ophthalmic solutions. The Specific Aims of Phase I are to 1): Conduct pre-formulation studies designed to develop suitable ..
  37. TIME RELEASE OPHTHALMIC DRUG DELIVERY INSERT
    BRUCE COHAN; Fiscal Year: 2002
    ..proposed commercial application: not available ..
  38. Gene Gun Technology, Opioids, and Corneal Diseases
    IAN ZAGON; Fiscal Year: 2003
    ..Ultimately, such data can be employed to design molecular strategies to remedy visual dysfunction. ..
  39. EARLY DETECTION OF GLAUCOMA DAMAGE
    Henry Jampel; Fiscal Year: 2004
    ..This assessment of the RTA and NFA will help to establish their utility as outcome measures for clinical management of glaucoma, epidemiological research, and clinical trials. ..
  40. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Henry Jampel; Fiscal Year: 2002
    ....
  41. GLAUCOMA SURGICAL OUTCOMES STUDY
    Henry Jampel; Fiscal Year: 2001
    ..The results of the study may allow physicians to reduce the morbidity of glaucoma surgery by altering their indications for surgery, surgical technique, and postoperative follow-up. ..
  42. PREVALENCE AND IMPACT OF GLAUCOMA AMONG THE VERY ELDERLY
    David Friedman; Fiscal Year: 2003
    ..Finally, the interactions between comorbidities (including cognitive deficits) and visual field loss will be explored. ..
  43. Controlled Drug Delivery to Colon Tumors Via Ultrasound
    WILLIAM PITT; Fiscal Year: 2006
    ..The research outcomes will prove hypotheses, which will become the basis for understanding and exploiting this therapy in the treatment of localized cancers, hopefully paving the way for clinical application. ..
  44. MOLECULAR STUDIES OF THE THIEL-BEHNKE CORNEAL DYSTROPHY
    Richard Yee; Fiscal Year: 2006
    ....
  45. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Rohit Varma; Fiscal Year: 2003
    ....
  46. Characterization of Tear Dynamics
    Jianhua Wang; Fiscal Year: 2007
    ..g. dry eye). [unreadable] [unreadable]..
  47. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Robert Ritch; Fiscal Year: 2003
    ....
  48. Advances in Allergy, Asthma and Immunology
    Leonard Bielory; Fiscal Year: 2002
    ..Summary: This application will provide the catalyst for establishing an ongoing forum for the review and promotion of scientifically based research assessing the impact of CAM in allergy, asthma and immunology. ..
  49. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 2008
    ..Candidate molecules for genetic susceptibility to glaucoma are likely to be identified. ..
  50. Localized modulation of RPE P-gp/MRP activity for back-of-the-eye drug delivery
    Soumyajit Majumdar; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  51. Analysis of Lacrimal Gland by Laser Microdissection
    John Ubels; Fiscal Year: 2003
    ..abstract_text> ..
  52. AMD AND RISK FACTORS IN A HISPANIC POPULATION
    Sheila West; Fiscal Year: 2003
    ..Such data will advance our understanding of the magnitude of AMD in this ethnic group, and the way in which risk factors relate to AMD in different populations. ..
  53. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Ronald Gross; Fiscal Year: 2003
    ....
  54. PUPILLARY RESPONSES AND COGNITIVE AGING IN SCHIZOPHRENIA
    Eric Granholm; Fiscal Year: 2004
    ..Abnormal age-related decline on these measures would suggest an abnormally accelerated depletion of processing resources with aging in schizophrenia in late life and would support the neurodegeneration hypothesis. ..
  55. Thymosin beta 4 and Autoimmune Ocular Surface Disease
    Gabriel Sosne; Fiscal Year: 2004
    ..abstract_text> ..
  56. Yearly Mass Treatment C. Trachomatis: When Can We Stop?
    Sheila West; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  57. Ophthalmic Antibiotic Resistance Study
    Kirk Wilhelmus; Fiscal Year: 2003
    ..abstract_text> ..
  58. Multifunctional Antioxidants as Anti-Cataract Agents
    Peter Kador; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  59. IMMUNOLOGY/MOLECULAR BIOLOGY TRAINING IN OPHTHALMOLOGY
    James Rosenbaum; Fiscal Year: 2007
    ..The quality of the institution, the talents of the specific faculty, the abilities of the applicant pool, and the proven success of the program areadditional strengths of this application. ..
  60. Artificial Cornea Based on Photolithographically Patterned, Biomimetic Hydrogels
    Christopher N Ta; Fiscal Year: 2010
    ..3. Determine the skirt design for optimal stromal tissue integration by evaluating in vitro and in vivo stromal wound healing within photolithographically patterned, microperforated hydrogel arrays. ..
  61. OCULAR HYPERTENSION TREATMENT STUDY (OHTS)
    Donald Budenz; Fiscal Year: 2008
    ....
  62. PATHOGENESIS OF CORNEAL EDEMA AFTER INTRAOCULAR SURGERY
    Henry Edelhauser; Fiscal Year: 2006
    ....